Stockscreener 앱 받기
0.9125
4.87%
0.0424
Immunic Inc 주식(IMUX)의 최신 뉴스
Immunic MS trial shows reduced brain lesionsICYMI - Proactive financial news
Immunic (IMUX) Price Target Lowered by D. Boral Capital to $4.00 - GuruFocus
What’s the beta of Immunic Inc. stock2025 Bull vs Bear & Accurate Intraday Trading Signals - mfd.ru
A Look At Immunic (IMUX) Valuation After CEO Transition MS Data And US$200m Financing - simplywall.st
Immunic prices private placement of up to $400 million - The Pharma Letter
Immunic secures up to $400 million in private placement financing By Investing.com - Investing.com Nigeria
Market movers: Moderna, Pinterest, DraftKings, Coinbase, Immunic... - Proactive financial news
Why Is Immunic Stock Soaring Friday? - Bitget
Immunic stock soars after $400 million private placement deal - Investing.com
Why Is Immunic Stock (IMUX) Up 27% Today? - TipRanks
Immunic Stock Jumps After Pricing $400 Million Private Placement - Bitget
Immunic secured US$400 million to conclude phase 3 MS program and prepare for launch - European Biotechnology Magazine
Immunic Inc’s Stock Volatility: Market Reactions and Financial Insights - StocksToTrade
Immunic’s private placement; Vertex’s cystic fibrosis data in young kids - Endpoints News
Immunic (IMUX) Shares Surge 26% on $400M Funding and Leadership Changes - GuruFocus
Immunic to raise up to $400M to fund late-stage MS trials, commercial push - Proactive financial news
Why Did IMUX Stock Surge 33% Pre-Market Today? - Stocktwits
Immunic announces private placement, CEO change (IMUX:NASDAQ) - Seeking Alpha
D. Boral Capital Lowers Immunic (NASDAQ:IMUX) Price Target to $4.00 - MarketBeat
Immunic secures up to $400 million in private placement financing - Investing.com
Immunic Secures $200M Financing to Advance MS Programs - TipRanks
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company - The Malaysian Reserve
Immunic, Inc. Plans Transition of Daniel Vitt from CEO - marketscreener.com
Immunic announces oversubscribed private placement of up to USD 400 million to accelerate transformation into commercial-stage company - marketscreener.com
Immunic stock soars after $400 million private placement deal By Investing.com - Investing.com UK
Biopharmaceutical company Immunic, Inc. announced that its co-founder and current CEO, Daniel Vitt, will work with the board of directors to initiate the search for a new CEO. - Bitget
Immunic Signs Multiple Material Agreements - TradingView
The latest round of funding raised by Immunic, Inc. is expected to strongly support the company's strategic transformation—from a biotechnology enterprise focused on research and development to a fully integrated commercial entity with a complete industry c - Bitget
Immunic Announces Oversubscribed Private Placement Of Up To USD 400 Million To Accelerate Transformation Into Commercial-Stage Company - TradingView
EQS-News: Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Companyboerse.de - boerse.de
Immunic shares gain on $400M raise to fund late-stage MS trials, commercial push - Proactive financial news
Can Immunic Inc. stock rebound after recent weaknessJuly 2025 Big Picture & Real-Time Buy Zone Alerts - mfd.ru
Can Immunic Inc. ride the EV waveIPO Watch & Safe Capital Growth Plans - mfd.ru
Immunic showcases Phase 2 data on vidofludimus calcium at ACTRIMS Forum - Proactive financial news
HC Wainwright Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX) - MarketBeat
IMUX: HC Wainwright & Co. Reiterates Buy Rating with $8 Target | - GuruFocus
Is Immunic Inc attractive for institutional investorsInsider Buying & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Brookline Cap M Predicts Immunic FY2025 Earnings - MarketBeat
Immunic (NASDAQ:IMUX) Upgraded at Brookline Cap M - MarketBeat
Analysts Set Expectations for Immunic FY2025 Earnings - MarketBeat
Immunic (NASDAQ:IMUX) Upgraded at Brookline Capital Management - Defense World
Brookline Capital Management Upgrades Immunic (NASDAQ:IMUX) to "Strong-Buy" - MarketBeat
Immunic to present additional data on MS drug at ACTRIMS forum - Investing.com Nigeria
Small cap wrap: Fineqia, Immunic, M2i Global, Trust Stamp… - Proactive Investors
Immunic to present additional data on MS drug at ACTRIMS forum By Investing.com - Investing.com South Africa
Immunic to present additional Phase 2 data on vidofludimus calcium in progressive MS - Proactive financial news
MS trial: Immunic therapy cuts brain lesions and EBV signals - Stock Titan
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis - Sahm
Buyback Watch: Is Sandisk Corporation stock a top performer YTDPortfolio Gains Report & Target Return Focused Stock Picks - baoquankhu1.vn
Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Chipmakers Recap: Is Immunic Inc stock a good dividend stockJuly 2025 Reactions & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Fed Meeting: Is Immunic Inc stock a good dividend stockWeekly Market Outlook & AI Driven Price Forecasts - baoquankhu1.vn
Insider Traders Lose US$42k As Immunic Drops - simplywall.st
Immunic (NASDAQ:IMUX) Trading Down 2.1%Here's Why - MarketBeat
1.12%
0.87%
자본화:
|
볼륨(24시간):